Bruna-Mejias Alejandro, San Martin Jessica, Arciniegas-Diaz Danna, Meneses-Caroca Trinidad, Salamanca-Cerda Amelia, Beas-Gambi Antonia, Paola-Loaiza-Giraldo Jessica, Ortiz-Ahumada Cynthia, Nova-Baeza Pablo, Oyanedel-Amaro Gustavo, Orellana-Donoso Mathias, Suazo-Santibáñez Alejandra, Sanchis-Gimeno Juan, Valenzuela-Fuenzalida Juan José
Departamento de Ciencias y Geografía, Facultad de Ciencias Naturales y Exactas, Universidad de Playa Ancha, Valparaíso 2360072, Chile.
Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello, Santiago 8370146, Chile.
Int J Mol Sci. 2025 Jun 19;26(12):5887. doi: 10.3390/ijms26125887.
The Mediterranean diet (MD) is one of the healthiest diets, high in fiber, antioxidants, and unsaturated fats. MD improves lipid profiles, reduces inflammation, controls blood pressure, decreases insulin resistance, and enhances the sensitivity to this hormone, lowering the risks of Metabolic syndrome (MS). MS is characterized by central obesity, hypertension, insulin resistance, and dyslipidemia, increasing the risk of cardiovascular disease and type II diabetes. The objective of this study was to know the effectiveness of the MD versus other treatments in patients with MS. A systematic search across multiple databases, Medline, Embase, Web of Science, Scopus, Google Scholar, and Cinahl, was conducted using keywords such as "Mediterranean diet", "Mediterranean food", "eat mediterranean", "Metabolic syndrome", and "x syndrome". A total of 12 studies met the inclusion criteria. Mediterranean diet at different doses versus other diets or other treatments showed significant improvements in clinical parameters, including BMI (mean difference of -0.83 95% CI: -0.93 to -0.74; < 0.00001),waist circumference (mean difference = -1.81, CI = -2.63 to -0.99, < 0.00001) triglycerides (mean difference = -22.38, CI = -32.86 to -11.90, < 0.00001), Glucose (mean difference = -4.28, CI = -7.64 to -0.93, = 0.005) and, HOMA IR (mean difference = -0.72, CI = -0.78 to -0.65, < 0.00001), and Insulin resistance (mean difference = -2.98, CI = -3.27 to -2.69, < 0.00001), all of which improved, Although there were more outcomes, these are the most important changes for patients with metabolic syndrome. MD improves metabolic and cardiovascular health, but study heterogeneity limits the results' generalizability. Because of that, further research is needed to standardize approaches and explore their mechanisms. MD should be part of an optimized strategy that includes education and physical activity. The strength of the evidence was very low according to the GRADE approach. Further research is needed to support the efficacy of the Mediterranean diet in patients with MS.
地中海饮食(MD)是最健康的饮食方式之一,富含纤维、抗氧化剂和不饱和脂肪。MD可改善血脂水平、减轻炎症、控制血压、降低胰岛素抵抗并增强对该激素的敏感性,从而降低代谢综合征(MS)的风险。MS的特征为中心性肥胖、高血压、胰岛素抵抗和血脂异常,会增加心血管疾病和II型糖尿病的风险。本研究的目的是了解MD与其他治疗方法相比对MS患者的有效性。使用“地中海饮食”、“地中海食物”、“食用地中海式饮食”、“代谢综合征”和“X综合征”等关键词,对多个数据库进行了系统检索,包括Medline、Embase、科学引文索引、Scopus、谷歌学术和护理学与健康领域数据库。共有12项研究符合纳入标准。不同剂量的地中海饮食与其他饮食或其他治疗方法相比,在临床参数方面有显著改善,包括体重指数(平均差值为-0.83,95%置信区间:-0.93至-0.74;P<0.00001)、腰围(平均差值=-1.81,置信区间=-2.63至-0.99,P<0.00001)、甘油三酯(平均差值=-22.38,置信区间=-32.86至-11.90,P<0.00001)、血糖(平均差值=-4.28,置信区间=-7.64至-0.93,P=0.005)以及稳态模型评估胰岛素抵抗(平均差值=-0.72,置信区间=-0.78至-0.65,P<0.00001)和胰岛素抵抗(平均差值=-2.98,置信区间=-3.27至-2.69,P<0.00001),所有这些指标均有所改善。虽然还有更多结果,但这些是代谢综合征患者最重要的变化。MD可改善代谢和心血管健康,但研究的异质性限制了结果的普遍性。因此,需要进一步研究来规范方法并探索其机制。MD应成为包括教育和体育活动在内的优化策略的一部分。根据GRADE方法,证据强度非常低。需要进一步研究来支持地中海饮食对MS患者的疗效。